Most sold healthcare stocks in Q3 2023

See which Healthcare stocks institutional investors trimmed or exited the most in Q3 2023, measured as net reductions in reported share positions from Q2 2023 into Q3 2023. Notable reductions at the top of this list include CODEXIS INC (CDXS), INCYTE CORP (INCY), GE HEALTHCARE TECHNOLOGY (GEHC), GILEAD SCIENCES INC (GILD). These rankings are based on SEC 13F filings from the investors we track.

SymbolNameNet sharesNet valueNewAddedTrimmedSold outHolding now
CDXSCODEXIS INC-4,885,641-$11.55M00111
INCYINCYTE CORP-2,870,904-$252.52M01213
GEHCGE HEALTHCARE TECHNOLOGY-2,511,082-$466.11M11318
GILDGILEAD SCIENCES INC-2,197,924-$166.13M03508
MRKMERCK & CO. INC.-1,982,533-$182.87M227113
SNYSANOFI-ADR-1,868,964-$121.34M02214
SENSSENSEONICS HOLDINGS INC-1,779,445-$1.36K00010
MRNAMODERNA INC-1,645,259-$194.47M02124
HLNHALEON PLC-ADR-1,618,002-$15.90M02406
GHGUARDANT HEALTH INC-1,595,998-$60.67M00111
JNJJOHNSON & JOHNSON-1,576,303-$138.95M1410218
PFEPFIZER INC-1,560,200-$58.45M138013
OCGNOCUGEN INC-1,550,005-$97400101
RHHBYROCHE HOLDINGS LTD-SPONS ADR-1,437,613-$54.92M00010
AGLAGILON HEALTH INC-1,403,786-$1.42M01203
ABTABBOTT LABORATORIES-1,360,240-$224.27M016010
BDXBECTON DICKINSON AND CO-1,347,989-$376.65M027110
IOVAIOVANCE BIOTHERAPEUTICS INC-1,282,087-$5.47M00111
VTRSVIATRIS INC-1,260,391-$1.24M00212
CMRXCHIMERIX INC-1,030,200-$1.51K00101
TMOTHERMO FISHER SCIENTIFIC INC-920,166-$436.86M246213
BBIOBRIDGEBIO PHARMA INC-915,854$204.57M10102
AUPHAURINIA PHARMACEUTICALS INC-867,400-$9.66K00101
ABCLABCELLERA BIOLOGICS INC-844,550-$8.60K00101
ACHCACADIA HEALTHCARE CO INC-825,758-$102.23M02103
MASIMASIMO CORP-771,607-$120.19M00020
HRTXHERON THERAPEUTICS INC-767,800-$92900101
VXRTVAXART INC-757,305-$55200101
FMSFRESENIUS MEDICAL CARE-ADR-709,084-$58.21M10113
SGMOSANGAMO THERAPEUTICS INC-701,742-$2.57K00101
CERSCERUS CORP-700,285-$18.32M00202
SDGRSCHRODINGER INC-687,052-$246.57M00112
JYNTJOINT CORP/THE-681,049-$12.14M01011
ARDXARDELYX INC-661,720-$1.43K00101
HCAHCA HEALTHCARE INC-628,125-$456.45M11115
NKTRNEKTAR THERAPEUTICS-585,000-$26500101
FATEFATE THERAPEUTICS INC-563,097-$2.97K00101
OGNORGANON & CO-558,955-$18.86M01304
DHRDANAHER CORP-501,666$36.86M127114
CNCCENTENE CORP-499,187$1.13M01203
ELANELANCO ANIMAL HEALTH INC-491,042$94.53M01203
BKDBROOKDALE SENIOR LIVING INC-482,818-$418.52K00202
CTLTCATALENT INC-480,264-$20.38M00101
ADAPADAPTIMMUNE THERAPEUTICS-ADR-478,515-$59100101
AMGNAMGEN INC-462,119-$43.05M11608
BNTXBIONTECH SE-ADR-445,019-$48.03K00010
NVAXNOVAVAX INC-438,883-$3.26K00010
DCGODOCGO INC-425,966-$4.79M10021
ERASERASCA INC-409,600-$1.72K00101
DVAXDYNAVAX TECHNOLOGIES CORP-341,703-$1.39K00101
20 symbols with net change in reported shares from tracked managers.−5.4M−4.0M−2.7M−1.3M0.00Net change in reported shares (tracked managers)CDXSINCYGEHCGILDMRKSNYSENSMRNAHLNGHJNJPFEOCGNRHHBYAGLABTBDXIOVAVTRSCMRXSymbol

Frequently asked questions about Most sold healthcare stocks in Q3 2023

  • What are the most sold Healthcare stocks in Q3 2023?

    The most sold healthcare stocks in Q3 2023 are those with the largest decrease in reported share counts across tracked institutional investors compared to Q2 2023, based on SEC 13F filings.

  • Which healthcare stocks did institutional investors trimmed or exited the most in Q3 2023?

    Among the managers we track, net reductions were largest in companies such as CODEXIS INC (CDXS), INCYTE CORP (INCY), GE HEALTHCARE TECHNOLOGY (GEHC), based on aggregated 13F data.

  • How is institutional selling calculated?

    Selling is calculated by summing the net decrease in shares reported by tracked investors between two consecutive quarterly 13F snapshots (compared to Q2 2023).

  • Does this include all institutional owners?

    These rankings are based on a subset of tracked institutional investors who file SEC 13F reports. While not exhaustive, the dataset includes many of the largest and most influential funds.

  • Are these trades real-time?

    No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.